CSL Ltd Annual Report 2021

Measure and commentary Threshold 50% Target 100% Maximum 150% Efficiency and Reliable Supply • Challenging plasma collection levels however multiple initiatives are driving solid growth • Delivery of a record-setting >100 million doses for the Northern Hemisphere 2020/2021 influenza campaign • Network strategy developed across global operations, incorporating strategic external supply partnerships to optimise production and distribution, and improve patient access, revenue and cost to serve • New Global Quality Management system implemented including new policies and standard operating procedures • Implementation of a new electronic safety management system • Improvement in ‘On Time and In Full’ performance outcomes • 25 plasma collection centres opened taking our total to 303 globally • Announcement of the new world-class biotechnology manufacturing facility in Melbourne Australia to supply influenza vaccines to Australia and the rest of the world with construction underway and on schedule • Major capital projects at all manufacturing sites progressing, including the opening of the ‘Protinus’ state-of-the-art immunoglobulin production facility in Bern Switzerland • Our ESG performance has again been recognised by the FTSE4Good Index Series – a leading sustainability index • CDP (formerly the Carbon Disclosure Project) performance outcome in line with the global and biotechnology/pharmaceutical sector for climate change and a slightly lower outcome than the global average for water security Digital Transformation • Appointment of our Chief Digital Officer • Creation of our Technology, Digital and Data strategy and transformation of our Information and Technology function to support the strategy • Enterprise-wide partnership arrangement with Capgemini to provide technology services and operations support 6.2 STI Outcomes by Executive KMP in 2021 The financial performance of CSL (NPAT and CFO) makes up the majority weighting of the KPIs for Executive KMP – 60%, incentivising the delivery of strong financial performance. Professor Cuthbertson is not eligible for any STI awards in 2021 under the executive remuneration framework. The NPAT at 30 June 2021 resulted in performance slightly above target and our CFO achieved a maximum performance outcome. The Board considered the quality of the financial performance, management of risk and the impact of COVID-19. The Board considered the outcomes for the STI financial metrics and determined not to use discretion to adjust these outcomes. However, in assessing the non-financial STI outcomes for Executive KMP for 2021 and ensuring appropriate balance between remuneration and performance, the Board exercised its discretion on the CEO’s KPIs relating to reduced plasma collections in 2021 due to factors associated with COVID-19. Achievements that contributed to the outcomes detailed in Table 3 below can be found in Table 2 of this Report. The Board made no adjustments under the Malus and Clawback Policy and no risk management, behaviour or compliance issues involving Executive KMP were identified during the joint consultation between the HRRC and ARMC. ● ● CSL Limited Annual Report 2020/21 86 Directors’ Report